T3D Therapeutics, Inc.
Durham, NC
- UEI
- NNGUW8XDL245
- CAGE
- 716M0
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 68 TW Alexander Dr, Durham, NC 27713, USA
- Website
- t3dtherapeutics.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Cognition Therapeutics, Inc. | Harrison, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Virogenics, Inc. | San Diego, CA | 238990 All Other Specialty Trade Contractors |
| Oligomerix Inc. | NY | — |
| Bolden Therapeutics Inc. | Providence, RI | — |
| Adrx, Inc. | Thousand Oaks, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
T3D Therapeutics, Inc. is a for-profit organization developing remedial therapeutics for Alzheimer's disease and other neurodegenerative diseases. The company is focused on developing a potentially disease-modifying, new drug called T3D-959 for the treatment of Alzheimer's disease and other central nervous system disorders. T3D-959 is a novel chemical entity and orally delivered small molecule that aims to improve dysfunctional brain glucose energy and lipid metabolism in patients with these conditions.
Through several prime federal grant awards, T3D Therapeutics has received substantial funding to advance the development of T3D-959. A $43.9 million grant from the National Institute on Aging supported a Phase 2 randomized, double-blind, placebo-controlled clinical trial of T3D-959 in mild to moderate Alzheimer's disease subjects. Another $2.5 million grant, also from the National Institute on Aging, is funding a 2-year rodent study to assess the long-term carcinogenic potential of T3D-959 as required by the FDA prior to market approval. The National Institute of Neurological Disorders and Stroke awarded a $2.7 million grant for Phase 2 enabling studies, including reproductive and developmental toxicology studies and manufacturing of clinical supplies, to support a planned therapeutic proof-of-concept trial of T3D-959 in Huntington's disease subjects through the NeuroNEXT clinical trials network. These awards reflect T3D Therapeutics' efforts to comprehensively advance T3D-959 through the drug development process for Alzheimer's disease and expand its therapeutic potential to other neurodegenerative indications like Huntington's disease.
Quick answers
Is T3D Therapeutics, Inc. registered in SAM.gov?
Yes. T3D Therapeutics, Inc.'s SAM.gov registration is active through March 3, 2027.
What is T3D Therapeutics, Inc.'s most recent federal award?
T3D Therapeutics, Inc.'s most recent federal grant award is Clinical development enablement ? Long term rodent testing of the carcinogenic potential of the alzheimer?s disease… (R44AG082580), from National Institute on Aging (NIH), on August 15, 2023.
On GovTribe
See T3D Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors